InvestSMART

Tryptamine Therapeutics Limited (ASX: TYP) - Announcements

Current share price for TYP : $0.034 0.002 (5.56%)+

ASX company news and announcements for Tryptamine Therapeutics Limited (TYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Tryptamine Therapeutics Limited (TYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Tryptamine Therapeutics Limited (TYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Tryptamine Therapeutics Limited (TYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Application for quotation of securities - TYP 13 Aug 2025 3:50PM $0.034 $0.034 fallen by 0%
- $2.6m in non-dilutive capital funding secured 12 Aug 2025 8:29AM $0.033 $0.034 risen by 3.03%
- Bioshares Biotech Summit Presentation 7 Aug 2025 1:32PM $0.033 $0.034 risen by 3.03%
- Regulatory permits secured for world first BED trial 7 Aug 2025 8:57AM $0.032 $0.034 risen by 6.25%
- Quarterly Activities Report and Appendix 4C 31 Jul 2025 3:57PM $0.030 $0.034 risen by 13.33%
- Patient recruitment for world first TRP-8803 trial underway 21 Jul 2025 8:26AM $0.033 $0.034 risen by 3.03%
- Key appointments strengthen TRP-8803 clinical development 16 Jul 2025 8:53AM $0.031 $0.034 risen by 9.68%
- Investor Presentation 26 Jun 2025 9:09AM $0.029 $0.034 risen by 17.24%
- Binge Eating Disorder Trial receives Human Ethics approval 23 Jun 2025 9:33AM $0.031 $0.034 risen by 9.68%
- Notification of cessation of securities - TYP 19 May 2025 3:06PM $0.036 $0.034 fallen by 5.56%
- Release from Escrow 16 May 2025 11:32AM $0.037 $0.034 fallen by 8.11%
- Initial Director's Interest Notice - HJ 14 May 2025 1:05PM $0.037 $0.034 fallen by 8.11%
- Final Director's Interest Notice - MD 14 May 2025 1:03PM $0.037 $0.034 fallen by 8.11%
- Herwig Janssen appointed as Chair and Director transition 12 May 2025 9:08AM $0.034 $0.034 fallen by 0%
- Quarterly Activities Report and Appendix 4C 30 Apr 2025 8:29AM $0.032 $0.034 risen by 6.25%
- TRP-8803 BED trial to commence with Swinburne this quarter 10 Apr 2025 9:15AM $0.031 $0.034 risen by 9.68%
- Change in substantial holding 3 Apr 2025 3:15PM $0.033 $0.034 risen by 3.03%
- Change of Company Secretary 31 Mar 2025 3:19PM $0.035 $0.034 fallen by 2.86%
- Change of Director's Interest Notice - DT 31 Mar 2025 2:28PM $0.034 $0.034 fallen by 0%
- Change of Director's Interest Notice - JC 31 Mar 2025 2:27PM $0.034 $0.034 fallen by 0%
- Change of Director's Interest Notice - CN 31 Mar 2025 2:25PM $0.034 $0.034 fallen by 0%
- Notification regarding unquoted securities - TYP 31 Mar 2025 2:09PM $0.034 $0.034 fallen by 0%
- Notification regarding unquoted securities - TYP 31 Mar 2025 2:03PM $0.034 $0.034 fallen by 0%
- Application for quotation of securities - TYP 31 Mar 2025 1:59PM $0.034 $0.034 fallen by 0%
- Proposed issue of securities - TYP 27 Mar 2025 6:25PM $0.037 $0.034 fallen by 8.11%

26 - 50 of 144 results

Page 2 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.